Markets:

Overview

News

Currencies

International

Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

3.650 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial ↗

April 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines ↗

April 21, 2022

Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for...

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 21, 2022

Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million.

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Analyst Ratings For Revance Therapeutics ↗

October 26, 2021

Within the last quarter, Revance Therapeutics (NASDAQ:RVNC) has observed t...

Via Benzinga

Revance Therapeutics: Q4 Earnings Insights ↗

February 28, 2022

Revance Therapeutics (NASDAQ:RVNC) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 26, 2022

Gainers Reneo Pharmaceuticals (NASDAQ:RPHM

Via Benzinga

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data ↗

January 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)...

Via Benzinga

SmileDirect Club Stock Isn’t Making a Comeback Any Time in the Near Future ↗

December 21, 2021

SmileDirect sells itself as a growth stock, selling orthodontic services directly through storefronts. But without growth, few are buying.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 14, 2021

Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $...

Via Benzinga

4 Stocks Insiders Are Buying ↗

November 30, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

Revance Therapeutics Inc (RVNC) Q3 2021 Earnings Call Transcript ↗

November 10, 2021

RVNC earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 25, 2021

Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 14.64% to $2.08 during Monday's regular session. The current volume of 7.2 million shares is 300.39% of Jaguar...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2021 ↗

October 25, 2021

Upgrades According to Wedbush, the prior rating for Regions Financial Corp (NYSE:

Via Benzinga

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 25, 2021

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 28.64% to $2.47 during Monday's pre-market session. The company's market cap stands at $38.1 million....

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 20, 2021

Gainers Sesen Bio (NASDAQ:SESN) stock increased by 29.2% to $1.3 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is 149.3 million...

Via Benzinga

46 Biggest Movers From Yesterday ↗

October 19, 2021

Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial...

Via Benzinga

Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher ↗

October 18, 2021

Toward the end of trading Monday, the Dow traded down 0.20% to 35,223.86 while the NASDAQ rose 0.68% to 14,998.54. The S&P also rose, gaining 0.19% to 4,480.05. The U.S. has...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 18, 2021

Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of...

Via Benzinga

Revance Stock Loses 40% Of Its Value After FDA Rejects Its Frown Lines Injection ↗

October 18, 2021

Revance Therapeutics tumbled Monday after the FDA rejected its frown lines injection.

Via Investor's Business Daily

Mid-Day Market Update: Nasdaq Rises 50 Points; Revance Therapeutics Shares Plummet ↗

October 18, 2021

Midway through trading Monday, the Dow traded down 0.05% to 35,275.96 while the NASDAQ rose 0.34% to 14,948.46. The S&P also rose, gaining 0.19% to 4,479.71. The U.S. has the...

Via Benzinga

Topics Stocks

34 Stocks Moving In Monday's Mid-Day Session ↗

October 18, 2021

Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare....

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates ↗

October 18, 2021

Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S....

Via Benzinga

Topics Stocks

These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday ↗

October 18, 2021

The Nasdaq looks poised to open slightly lower after a strong week.

Via The Motley Fool

Topics Stocks

10 Biggest Price Target Changes For Monday ↗

October 18, 2021

Barclays reduced the price target for The Walt Disney Company (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 18, 2021

Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion....

Via Benzinga

Why Revance Therapeutics Stock Is Getting Crushed Today ↗

October 18, 2021

A surprise rejection is weighing on the biopharma's shares today.

Via The Motley Fool

21 Stocks Moving in Monday's Pre-Market Session ↗

October 18, 2021

Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

Headline News about Revance Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today